ArticleESMO real world data and digital oncology2026
Early-onset gastrointestinal cancer patterns in Navarre: incidence, tumour features and patient survival outcomes.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite growing awareness of the rising incidence and particular features of early-onset gastrointestinal cancer (EOGIC), evidence from Spain remains limited. The purpose of this study was to compare EOGIC with average-onset gastrointestinal cancer (AOGIC) in Navarre, by analysing incidence trends, clinicopathological features and patients' relative survival (RS). Materials and methods: Patients with EOGIC (18-49 years) and AOGIC (≥50 years) diagnosed with colorectal, gastroesophageal, pancreatic and hepatobiliary cancer between 2015 and 2025 were considered. Incidence trends were evaluated using age-standardised incidence rates and annual percentage changes (APCs); survival outcomes were estimated through RS and relative excess risk (RER). Results: A total of 5053 patients were included, of whom 5.38% were EOGIC. Although the incidence of AOGIC declined (APC = -2.80, Conclusions: The incidence of EOGIC in Navarre remained stable, whereas AOGIC declined. Patients with EOGIC were mostly females, presented with more aggressive tumours and had lower stage-adjusted mortality risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.